Clinical Trials

6 trials
RecentStart dateEnrollment
Temozolomide × Other hematologic neoplasm × Clear all
NCT01618136 2023-06-18

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1/2 Completed
41 enrolled
BreastGynecologicLymphoidOther hematologic neoplasm

Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Triple Negative Breast Neoplasms

NCT00003567 2010-06-11

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
8 enrolled
CNSLymphoidOther hematologic neoplasmSarcoma

Astrocytoma, Brain Neoplasms, Burkitt Lymphoma, Ependymoma, Glioblastoma, Glioma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Oligodendroglioma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma